S100A9/12—another significant marker of CD52+ Mp reported here and by Alivernini et al.—has the potential to induce inflammation in fibroblast with the production of TNF-α and IL-6 and persist in remission RA, supporting our hypothesis above (10, 21). Here, S100A9 is linked to rheumatoid arthritis.